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gene found that actually would retard the
development ofbreast tumors-and it seems
to do that," said Anne Bowcock, a breast
cancer researcher and associate professor of
pediatrics at the University of Texas
Southwestern Medical Center in Dallas. "I
think it's a significant step toward the treat-
ment of at least some breast cancers." Most
ofthe 184,000 new breast cancer cases diag-
nosed annually are not the inherited type.
But the new research suggests that the pro-
tein produced by normal BRCA1 genes may
be effective against the more common non-
inherited forms ofbreast cancer.
Researchers led by Jeffrey Holt of
Vanderbilt first implanted normal BRCA1
genes into human breast and ovarian cancer
cells and found that cell growth was inhibit-
ed in vitro. Next, the researchers stably trans-
ferred either normal or mutant BRCA1 genes
into breast cancer cells and injected the cells
into mice. Tumors developed in all 15 mice
given mutant BRCA1, but in none ofthe 20
mice given normal BRCAI. Finally, the
researchers injected viruses carrying the
BRCA1 gene into the abdomens of 10 mice
with established breast cancer tumors; half
the mice got normal BRCA1, the others got
mutated BRCA1. The mice with mutant
BRCA1 all died ofcancer within two weeks.
Those with normal BRCA1 survived 15 to
41 days, and their tumors either shrank or
disappeared.
All the experiments used a cell line
derived from noninherited breast cancer, sug-
gesting that the treatment might work
against the more common types of the dis-
ease. Against hereditary breast and ovarian
cancer, "presumably it would have an even
more dramatic effect-at least that's what we
hope," said RoyJensen, an assistant professor
ofpathologyand cell biology atVanderbilt.
Translating the results into treatments
for human cancers will take time. "It's going
to be a long time before this is taken to the
bedside," said Bowcock. "The problem is
actually getting BRCA1 into breast cells-it's
not going to be easy."
It's easier to get BRCA1 into ovarian
tumor cells, and Vanderbilt researchers
recently began clinical trials using BRCA1 on
about 20 ovarian cancer patients, a move
that concerns some of their colleagues.
While he finds the results ofthe mouse and
cell culture experiments "intriguing" and
"encouraging," Roger Wiseman, head ofthe
Comparative Carcinogenesis Group of the
NIEHS Laboratory of Molecular
Carcinogenesis (part ofthe team that identi-
fied BRCA1) feels the human gene therapy
trials are "premature, based on the data that
have been presented so far." Wiseman would
like to see more animal studies performed
before BRCAJ is used in patients.
A related study led by Jensen found evi-
dence that the BRCA1 protein may be
secreted and do its work outside the cell. If
this is true, it would be much easier to
design and deliver drugs that mimic the pro-
tein's effects. However, this finding is con-
troverted, and other research groups are con-
vinced that the BRCA1 protein works from
inside cells.
"What we need to do to confirm our
theory is purify recombinant BRCAJ and
put it onto cells and see if it actually has a
growth inhibitory action," said Jensen. If it
does, and if it works only on breast and
ovarian cancer cells and not other cells,
"then that's pretty good evidence that there
are specific receptors for this protein. Our
efforts then would be focusing on trying to
find those receptors."
Fueling the Gas Debate
New findings continue to fuel the debate
over the safety and effectiveness of gasoline
additives, such as methyl tertiary butyl ether
(MTBE) and ethanol, being used to reduce
air pollution. The Clean Air Act
Amendments of 1990 required that, begin-
ning in 1992, areas that fail to meet air qual-
ity standards must use oxygenated fuels. Not
only has the effectiveness of the oxygenates
in reducing carbon monoxide (CO) emis-
sions been questioned, the additives have
also been accused ofcausing health problems
including headaches, dizziness, nausea, and
rashes. However, a recent study has found
that the additives are successful in reducing
CO emissions and do not appear likely to
substantially increase health risks when com-
pared to normal gasoline. The report
Genetics and Biosafety
With the pounding pace at which research in genetics and biotechnology is progressing, it
has become increasingly difficult forscientists to stayabreast ofall the advances and ensure
that the new technology is being used in a safe and cautious manner. In an effort to
improve communications among scientists and promote the safe use ofbiotechnology, the
United Nations established the International Centre for Genetic Engineering and
Biotechnology (ICGEB).
The center maintains two main research laboratories, one in Trieste,
Italy, and another in New Delhi, India, with several other smaller labs scat-
tered around the world. These laboratories distribute their findings along
with other biology-related information over the Internet via the ICGEB
home page and ICGEBnet, an information resource network for molecular
biologists.
The ICGEB home page, located athttpdJ/bascicgeb.trieit/, provides
information on ICGEB-sponsored meetings and symposia, access to biology-
related databases and newsgroups, and information on accessing ICGEBnet. 3)
Asecond biology-related network available from the home page called BIN21 is still being
developed bytheICGEB andwill focus on issues ofbiodiversity.
Among the databases accessible from the ICGEB's home page is one relating to P450
proteins and P450-containing systems, an on-line directory ofbiologists around theworld,
and SBASE (a sequence database ofprotein domains). An extensive library of biosafety-
related rules andregulations fromvarious nations, organizations, and research institutions is
also available, along with lists of experts and databases that can be contacted to help
researchers in dealing with biology-related legal issues. For further assistance on biosafety
and legal questions, a link is provided to the Stockholm Environment Institute's
Biotechnology Advisory Board home page. This international board of scientists will
answer questions and give advice on any issue relating to ecology, biochemistry, genetics,
biotechnology, pathology, environmental law, oreconomics.
Access to ICGEBnet andBIN21 will be free ofcharge butgenerally limited to scientists
andpolicymakers with apertinent interest in biology. Currently, ICGEBnet gives scientists
around theworld access to avarietyofdatabases andprovides acomputer environment that
allows molecular biologists to analyze nudeotide and protein sequences. Analysis software,
induding three major program packages, is distributed over ICGEBnet. In addition, infor-
mation services such as electronic mail and bulletin boards are also available. The center's
goal is to distribute these services to areas ofthe developing world where they are not yet
widelyavailable.
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emphasizes that further research is needed,
but recommends that the use ofthe additives
should not be abandoned at this time.
The Potential Health Effects ofOxygenates
Added to Gasoline: A Review ofthe Current
Literature was released in April by the
Cambridge, Massachusetts-based Health
Effects Institute, a cooperative effort of the
EPA and the auto industry created to exam-
ine the health effects ofmotor vehicle emis-
sions. HEI conducted a review of existing
research, public complaints, and occupation-
al exposures concerning gasoline additives.
According to the report, potential health
effects from exposure to gasoline containing
MTBE include headaches, nausea, and sen-
sory irritation; acute, reversible neurotoxic
effects (based on studies with rats at high
exposure levels); and cancer (based on
increased frequency of tumors in rats and
mice at high exposure levels). Exposure to
ethanol by ingestion of moderate to large
quantities has been found to increase the risk
ofcancer, adversely affect embryos, and pro-
duce neurotoxicity. However, the report
points out that these effects are unlikely to
occur at low levels ofinhalation.
The report concludes that possible short-
term and cancer-causing effects of exposure
to gasoline without oxygenates are similar to
those from exposure to gasoline with oxy-
genates. Adding oxygenates to gasoline
reduces the emission of carbon monoxide
and benzene from motor vehicles, which
may lower health risks for some people, the
report stated. However, the process may
increase exposure to oxygenates and aldehy-
des, which may have other health risks. The
report concluded that an immediate reduc-
tion in oxygenate use is not warranted at this
time because adding oxygenates is unlikely to
significantly increase health risks associated
with fuel use.
The report recommends that further
research be conducted and outlines several
priorities, including comprehensive assess-
ments of personal exposure to oxygenates,
human environmental chamber studies to
evaluate the health effects of MTBE and
MTBE-gasoline mixtures, epidemiologic and
animal studies to evaluate cancer risks of
MTBE, and comprehensive assessments of
other oxygenates.
The study was commissioned by the
EPA and the Centers for Disease Control
and Prevention (CDC) as part of a broad
review of oxygenated fuels being conducted
by the White House Office of Science and
Technology Policy, which will examine air
quality benefits, engine performance, fuel
economy, and costs of the fuels. The HEI
study's conclusions are similar to those of a
recent National Science and Technology
Council report conducted by an interagency
IARC on Tamoxifen
Tamoxifen, an antiestrogenic compound that has been recognized by the World Health
Organization as an essential drug for the treatment ofbreast cancer, is itselfcarcinogenic,
according to the International Agency for Research on Cancer. IARC researchers, who
met in February in Lyon, France, reviewed evidence on the potential carcinogenicity of
13 pharmaceuticals. Though they found evidence that tamoxifen increases a woman's
risk of developing endometrial cancer, they emphasized that this does not abate the
drug's benefits.
"No woman being treated for breast cancer should have [her] treatment stopped
because of the condusions of the [IARCI working group," the researchers concluded.
"The risk ofendometrial cancer is
far lower than the benefits women
with breast cancer receive from
tamoxifen."
Tamoxifen has been pre-
scribed to women with metastatic
breast cancer for over 20 years and
it is registered for use in nearly
100 countries. It has been used as
both a curative agent and a sec-
ondary cancer-preventive agent,
4<
and it is also being evaluated for use as a primary preventive agent for healthywomen at
an increased risk ofdeveloping breast cancer, LARC director Paul Kleihues said in a 17
February 1996 artide in TheLancet.
The IARC group, which consisted of 19 scientists from 8 countries, reviewed all the
published scientific data on second primary tumors reported in patients who were given
tamoxifen as treatment for breast cancer. In a draft ofthe study results, the group con-
cluded that there was "sufficient evidence in humans forthe carcinogenicity oftamoxifen
in increasing the risk ofendometrial cancer." However, the group also recognized that
"there is condusive evidence that tamoxifen reduces the risk ofcontralateral breast can-
cers" (second cancers in the other breast), and that "there is inadequate evidence tamox-
ifen affects the riskofothercancers." Theresults ofthestudywill bepublished involume
66 ofthe L4RCMonographs on theEvaluation ofCarcinogenicRisks toHumans.
Though statements on adrug's benefits are not normally induded in the Monographs
series, Kleihues told TheLancetthat the working group would probably make an excep-
tion for tamoxifen. Such a statement may help quell the concerns ofthose worried that
an overzealous reaction to IARC's findings could stop the use ofaverybeneficial medica-
tion. Criticism of the agency's decision to evaluate the carcinogenicity of tamoxifen
began late lastyearwhen thestate ofCalifornia, in response, considered listingtamoxifen
as a carcinogen under its Proposition 65. Critics point out that IARC's report could
cause tamoxifen to bequicklyreplaced byanyofanumberofnewantiestrogens currently
being introduced. With comparatively little human data available on the new drugs, the
danger exists that tamoxifen will be uncritically replaced by a less effective or more toxic
medicine.
Kleihues said that IARC received manyletters concerning its studyon tamoxifen, but
that the agencydid not cancel or reschedule the evaluation as a matter ofprinciple. "It is
important that women have access to scientific opinion on the low risks ofendometrial
cancer," Kleihues and working group chairman George Lucier stated in a press release,
"so thattheycan make informed decisions on the treatmenttheywill accept."
Tamoxifen is one ofthree triphenylethylene antiestrogenic compounds that will be
reviewed in volume 66. The other two, droloxifene, a drug also used in the treatment of
breast cancer, andtoremifene, which isjust beingintroduced, were found to be "not clas-
sifiable" as to theircarcinogenicity to humans dueto inadequate data.
Similar results were found for six ofa group ofseven benzodiazepines and benzodi-
azepine analogues that are used in the treatment ofinsomnia, anxietydisorders, and alco-
holwithdrawal. One, oxazepam, was found to be"possiblycarcinogenic to humans."
Twocholesterol-lowering drugs, dofibrate andgemfibrozil, werealso found to be "not
classifiable" as totheircarcinogenicity to humans. Phenytoin, which is used to treatepilep-
syand certain cardiacarrhythmias, was foundto be"possiblycarcinogenic to humans."
IARC has evaluated the carcinogenicity ofmore than 800 agents. Ofthese, 70 have
been deemed human carcinogens andabout ahalfdozenofthese arestill in use.
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panel, says Mary White, an epidemiologist
with the CDC. "Both reports clearly state
that the information available on the addi-
tives is very limited." White emphasized the
need for additional research. "There are some
troubling and unanswered questions about
the acute health effects [of the oxygenates].
These are a real concern, which no one dis-
misses, but we're talking about acute
headaches, not acute mortality," White said.
Representatives of the oil industry who
support the use of oxygenates were satisfied
with the report's conclusions. "HEI did a
good job of reviewing the information. I
found the report to be favorable, although it
overemphasized the carcinogenesis [of the
oxygenates]," said Robert Drew, director of
health and environmental research for the
American Petroleum Institute. "Even though
the results highlighted the carcinogenic and
neurotoxic endpoints, [HEI] was not con-
cerned enough for the materials to be taken
offthe market in the short term," he said.
However, the HEI report findings have
angered opponents ofoxygenate use, includ-
ing Myron Mehlman, a staffscientist at the
Environmental and Occupational Health
Sciences Institute at Rutgers University.
Mehlman, who feels that the additives
should be immediately removed from the
market, says the HEI report does not accu-
rately address the acute effects of the oxy-
genates, and he criticized the studies cited in
the report. "I don't know ofany studies that
have been conducted [on oxygenates] that
are adequate," he said. Mehlman also says
there are not sufficient data to show that the
additives reduce carbon monoxide emissions;
therefore, using the oxygenates is causing
unnecessary health risks. Drew counters,
"MTBE at this point is a thoroughly studied
chemical. We concur with the conclusion
that MTBE is certainly no more harmful
than gasoline itself."
Although HEI acknowledges that it is
not possible to have complete information
about a substance before it is used, the report
said that, in the future, more research-
including a comprehensive testing program,
rigorous exposure assessment, and epidemio-
logic studies-should be conducted before
introducing a substance into widespread use.
Human Interactions with the
Environment:
Perspectives from Space
August 20-22, 1996
Ramkota Inn
Sioux Falls, South Dakota
The principal objectives of the Pecora 13 Symposium are:
1. To better identify information requirements, and determine current information deficiencies for
addressing issues related to human interaction with the environment.
2. To report progress in mapping, monitoring and characterizing the biosphere and the extent and
nature of human activity via remote sensing technology.
3. To define opportunities for enhancing progress in using remote sensing to enhance the quality of
human life and for protecting the global environment.
For more information:
Pecora 13 Symposium
PO Box 1607
Sioux Falls, SD 57101-1607
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